- $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources -
- Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study of MM-121 in metastatic non-small cell lung cancer and Phase 1 study of MM-310 in solid tumors -
- Conference call at 8:30 am ET today -
PR Newswire
CAMBRIDGE, Mass., Aug. 7, 2018